Letter: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349-53).

Letter: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349-53). Diabetes Metab J. 2020 Jun;44(3):480-481 Authors: Jeon JY PMID: 32613779 [PubMed - in process]
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research

Related Links:

We present the unique opportunity we had to monitor the liver, IL-6 and immune cell course before, during and after COVID-19 in a boy with autoimmune hepatitis (AIH) and type 1 diabetes (T1D). CD4+ and CD8+ T cells frequencies decreased because of prednisolone, followed by a plateauing increase whereas CD19+CD20+ B cell increased strongly and was unaffected by COVID-19 infection. Moreover, the percentage of activated CD8+ T cells expressing HLA-DR (CD8+HLA-DR+) increased during COVID-19 and subsided after its clearance. Total regulatory T cells (Tregs: CD4+CD25+CD127lowFOXP3+) remained stable. Although activated Tregs (CD4...
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Case Reports Source Type: research
This study aimed to analyse the clinical characteristics and abnormal immunity of the confirmed COVID-19 non-survivors.MethodsIn this single-centered, retrospective, observational study, we enrolled 125 patients with COVID-19 who were died between January 13 and March 4, 2020 in Renmin Hospital of Wuhan University. A total of 414 randomly recruited patients with confirmed COVID-19 who were discharged from the same hospital during the same period served as control. The demographic, clinical characteristics and laboratory findings at admission, and treatment used in these patients were collected. The immunity-related risk fa...
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research
Publication date: Available online 1 August 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Smita Rath, Alakananda Tripathy, Alok Ranjan Tripathy
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
CONCLUSION: Clinical pharmacists should participate in the optimization of drug treatment programs and provide pharmaceutical care for critically ill COVID-19 patients; this can promote the rational use of drugs. PMID: 32729823 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Authors: Hase R, Kurata R, Ishida K, Kurita T, Muranaka E, Mito H Abstract A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
TYPE 2 DIABETES is the blood sugar condition that needs to be well managed. Diabetics are more vulnerable to developing a severe illness if they catch coronavirus, but it's still possible to have a safe staycation.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
A 73-YEAR-OLD MAN (weight 69 kg, height 175 cm) was transferred to the authors ’ critical care unit with respiratory and acute renal failure secondary to coronavirus disease 2019 (COVID-19) infection. His past medical history included hypertension, diabetes, and previous stroke, from which he had made a full recovery. The patient was treated with mechanical ventilation and p eritoneal dialysis. He was recruited into the hydroxychloroquine arm of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Diagnostic Dilemma Source Type: research
Authors: Sandooja R, Vura NVRK, Morocco M Abstract Coronavirus disease-19 (COVID-19) can manifest as fever, cough, and shortness of breath and is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Occasionally, these patients may present with diabetic ketoacidosis (DKA). Patients with comorbidities such as diabetes mellitus and hypertension, as well as older age groups, are known to have a more severe disease progression and poor prognosis. In this review article, we attempt to better understand the disease process in diabetics and also discuss potential mechanisms by which diabetes may play a ...
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
Abstract OBJECTIVE: We aimed to observe the clinical characteristics of coronavirus disease 2019 (COVID-19) patients with overweight and obesity. METHODS: Consecutive COVID-19 patients from 10 hospitals of Jiangsu province, China were enrolled. RESULTS: 297 COVID-19 patients were included. 39.39% and 13.47% of patients were overweight and obese, respectively. The proportions of bilateral pneumonia (92.50% vs. 73.57%, P=0.033) and type 2 diabetes (17.50% vs. 3.57%, P=0.006) were higher in patients with obesity than lean patients. The proportions of severe illness in patients with overweight (12.82% vs. 2....
Source: Obesity - Category: Eating Disorders & Weight Management Authors: Tags: Obesity (Silver Spring) Source Type: research
This study is open label.Numbers to be randomized (sample size)For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. An interim analysis on efficacy is planned using standard alpha-spending function.For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 30...
Source: Trials - Category: Research Source Type: clinical trials
More News: Coronavirus | COVID-19 | Diabetes | Endocrinology